Li Ruixi, He Ting, Xing Zhichao, Mi Li, Su Anping, Wu Wenshuang
Division of Thyroid Surgery, Department of General Surgery and Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
Division of Thyroid Surgery, Department of General Surgery and Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
Autoimmun Rev. 2025 May 30;24(6):103783. doi: 10.1016/j.autrev.2025.103783. Epub 2025 Mar 2.
Hashimoto's thyroiditis (HT) is one of the most prevalent endocrine disorders worldwide, and it can occur in people of all ages, including children. HT has a multifactorial pathogenesis and develops after a combination of gene regulation, environmental modifiers, and infection triggers. Various coamplifying feedback chronic inflammatory systems are involved in immune mechanisms, including oxidative stress, lymphocyte infiltration, and thyroid cell death. Furthermore, there is no effective treatment for HT at their roots. Thus, this review systematically summarizes and updates the existing etiology and pathogenesis, potential malignant transformation, emerging therapeutic drugs and animal model construction, making it more convenient for researchers to obtain effective information about HT and better explore potential strategies for short-term treatment of the disease.
桥本甲状腺炎（HT）是全球最常见的内分泌疾病之一，可发生于包括儿童在内的各年龄段人群。HT发病机制具有多因素性，是在基因调控、环境修饰因素和感染诱因共同作用后发展而来。多种协同放大的慢性炎症系统参与免疫机制，包括氧化应激、淋巴细胞浸润和甲状腺细胞死亡。此外，目前尚无针对HT根本病因的有效治疗方法。因此，本综述系统总结并更新了现有的病因和发病机制、潜在恶性转化、新兴治疗药物及动物模型构建等内容，以便研究人员更便捷地获取有关HT的有效信息，并更好地探索该疾病的短期治疗潜在策略。
